Atropine is a well-established pharmaceutical agent that has been used in ophthalmology for over a century. At very low concentrations (0.01 to 0.05 percent), atropine has been shown to slow axial elongation of the eye — the structural change that drives myopia progression — with minimal impact on pupil size or near focusing ability.
The exact mechanism is still being studied, but current evidence suggests that low-dose atropine acts on muscarinic receptors in the sclera and choroid, modulating biochemical signals that regulate eye growth. The landmark ATOM and LAMP studies — conducted over multiple years with thousands of children — established that concentrations between 0.01 and 0.05 percent provide meaningful slowing with the best side-effect profile.
Dr. Patel selects the atropine concentration based on your child's age, current prescription, rate of progression, and whether other myopia control treatments are already in place. Dosing can be titrated up or down over time based on treatment response.
Combination power: Low-dose atropine is frequently paired with ortho-k or MiSight for children whose myopia is progressing aggressively — delivering additive slowing that neither treatment achieves alone.
Why Atropine Therapy
The simplest possible routine — one drop in each eye before sleep. No lenses to insert, remove, or clean.
The ATOM and LAMP trials provide robust, multi-year evidence for atropine's safety and efficacy in children.
Easily paired with ortho-k, MiSight, or Stellest lenses for enhanced myopia control in fast progressors.
Can be prescribed for children as young as 4-5 — before they are ready for contact lenses.
At 0.01-0.05% concentration, most children experience no noticeable pupil dilation or near-vision blur.
Concentration can be titrated from 0.01% to 0.05% based on your child's response and progression rate.
Dr. Kumar Patel, Diplomate of the American Board of Optometry, lectures across Texas on myopia control and prism therapy.
We use axial length biometry and cycloplegic refraction to objectively guide atropine concentration decisions.
If atropine alone is insufficient, we seamlessly add ortho-k, MiSight, or Stellest lenses for combination therapy.
Conveniently located at 2600 Lakeside Parkway, Suite 180, Flower Mound, TX 75022 — proudly serving Flower Mound, Highland Village, Lewisville, Grapevine, Coppell, Lantana, Argyle, and the greater DFW area.
Frequently Asked Questions
At concentrations of 0.01 to 0.05 percent, side effects are minimal. Some children experience mild light sensitivity or slight near-vision blur, but these effects are far less pronounced than with higher-dose atropine. Most children and parents report no noticeable side effects at the lowest concentrations.
Treatment duration depends on your child's age, progression rate, and response. Most children continue low-dose atropine for two to three years, sometimes longer. Dr. Patel monitors progression at each visit and adjusts the plan accordingly. When drops are discontinued, we watch closely for any rebound progression.
Currently, low-dose atropine for myopia control is available through compounding pharmacies that prepare the drops in precise concentrations (0.01, 0.025, or 0.05 percent). Dr. Patel works with trusted compounding pharmacies that follow strict quality standards to ensure accurate dosing and sterility.
Yes. Combination therapy is one of the most effective strategies for children with aggressive myopia progression. Dr. Patel frequently pairs low-dose atropine with orthokeratology or MiSight lenses when a single treatment alone is not providing sufficient slowing. Research supports the additive benefit of this approach.
Low-dose atropine can be prescribed for children as young as 4 or 5, making it one of the earliest interventions available. It is particularly useful for very young children who are not yet ready for contact lenses. There is no strict upper age limit — teenagers with progressing myopia can also benefit.